1,445 reports of this reaction
2.7% of all TICAGRELOR reports
#6 most reported adverse reaction
CHEST PAIN is the #6 most commonly reported adverse reaction for TICAGRELOR, manufactured by AstraZeneca Pharmaceuticals LP. There are 1,445 FDA adverse event reports linking TICAGRELOR to CHEST PAIN. This represents approximately 2.7% of all 52,671 adverse event reports for this drug.
TICAGRELOR has an overall safety score of 85 out of 100. Patients taking TICAGRELOR who experience chest pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CHEST PAIN is a less commonly reported adverse event for TICAGRELOR, but still significant enough to appear in the safety profile.
In addition to chest pain, the following adverse reactions have been reported for TICAGRELOR:
The following drugs have also been linked to chest pain in FDA adverse event reports:
CHEST PAIN has been reported as an adverse event in 1,445 FDA reports for TICAGRELOR. This does not prove causation, but indicates an association observed in post-market surveillance data.
CHEST PAIN accounts for approximately 2.7% of all adverse event reports for TICAGRELOR, making it a notable side effect.
If you experience chest pain while taking TICAGRELOR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.